Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 716

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 2
Chunk 716
---
3.

Summary
Compensation Table

The
following table provides information regarding the compensation of our named executive officers during the years ended December
31, 2024 and 2023.

    Name and Principal Position 
    Year  
    Salary  
    Bonus  
    Option Awards  
    Non-Equity Incentive Plan Compensation  
    All Other Compensation  
    Total 

    Francis Knuettel II 
     2024  
    $424,923  
    $56,666  
    $361,833  
    $—  
    $—  
    $843,422 

    Chief Executive and Chief Financial Officer 
     2023  
    $107,500  
    $—  
    $199,510  
    $—  
    $—  
    $307,010 

    Eric Lang(1) 
     2024  
    $446,154  
    $—  
    $230,318  
    $—  
    $—  
    $676,472 

    Chief Medical Officer 
     2023  
    $166,767  
    $—  
    $120,735  
    $—  
    $—  
    $287,502 

    Christian Kopfli 
     2024  
    $—  
    $—  
    $—  
    $—  
    $—  
    $— 

    Former Chief Executive Officer, Former Chief Strategy Officer, and Former Vice Chairman (2) 
     2023  
    $11,280(3)  
    $—  
    $149,633  
    $—  
    $—  
    $160,913 

    (1) 
    Represents the portion
    of Dr. Lang’s salary attributable to his services to the Company during the year ended December 31, 2023. Dr. Lang was
    appointed Chief Medical Officer of the Company, effective May 15, 2023.

    (2) 
    Mr. Kopfli stepped
    down as Chief Financial Officer with the hiring of Mr. Knuettel, effective June 10, 2022. In addition, in July 2023, Mr. Knuettel
    assumed the role of Interim Chief Executive Officer and stepped down as